Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055696 | 0.85 | ALDH1A1 (0.61) | HPGDALDH1A1TSHRGLAMEN1 | |
| SCHEMBL4058262 | 0.82 | ALDH1A1 (0.58) | HPGDALDH1A1TSHRGLAMEN1 | |
| SCHEMBL18765958 | 0.81 | ALDH1A1 (0.66) | HPGDALDH1A1TSHRGLAMEN1 | |
| SCHEMBL18325693 | 0.80 | HPGD (0.66) | HPGDALDH1A1TSHRGPR88LMNA | |
| SCHEMBL13889056 | 0.80 | HPGD (0.76) | HPGDTSHRGPR88LMNAMEN1 | |
| SCHEMBL4061019 | 0.79 | ALDH1A1 (0.54) | HPGDALDH1A1TSHRGLAMEN1 | |
| SCHEMBL1114963 | 0.79 | ALDH1A1 (0.54) | HPGDALDH1A1TSHRGLAMEN1 | |
| SCHEMBL12679897 | 0.78 | ALDH1A1 (0.53) | HPGDALDH1A1TSHRGLAMEN1 | |
| SCHEMBL11618038 | 0.78 | ALDH1A1 (0.61) | HPGDALDH1A1TSHRGLALMNA | |
| SCHEMBL7497334 | 0.78 | ALDH1A1 (0.61) | HPGDALDH1A1TSHRGLAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | HPGD 215/4885ALDH1A1 532/4885TSHR 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.